Satellite Symposia Programme
Saturday 15 April -13:30 – 15:00 BST
Organised by UCB Biopharma SRL
BMD and clinical decision making in osteoporosis: Are we exploiting the full potential?
Meeting Room: Room 3AB
| 13:30–13:35 | Welcome and introduction Polyzois Makras (Greece) |
| 13:35–13:55 | Reappraisal of surrogate markers in osteoporosis: A focus on BMD* |
| 13:55–14:15 | BMD assessment in clinical decision-making: Current and potential applications* |
| 14:15–14:40 | Optimising gains in BMD: What does ‘good’ look like and how do we get there? |
|
*Insights from with discussion facilitated by |
|
| Q&A/faculty discussion All |
|
| 14:55–15:00 | Conclusions and closing remarks Polyzois Makras (Greece) |
Sunday 16 April – 12:15 – 13:15 BST
Inozyme Pharma
Beyond XLH – Mechanisms and Manifestations of Hypophosphatemic Rickets
Meeting Room: Room 3AB
| 12:15 – 13:15 | This program will review the pathophysiology and clinical presentation of often underrecognized forms of FGF-23 mediated hypophosphatemic rickets, and present strategies for optimizing diagnosis. Lothar Seefried (Germany) |
Sunday 16 April – 14:45 – 15:45 BST
Kyowa Kirin International plc
Staying on the path to long-term treatment success in XLH
This event is intended for healthcare professionals only who are registered for ECTS 2023. This promotional symposium is organised and funded by Kyowa Kirin and will contain data about Kyowa Kirin products.
Draft agenda subject to change. KKI/INT/CYS/0142 I March 2023
Meeting Room: Hall 1B
| 14:45 | Welcome and introductions Stuart Ralston (United Kingdom) |
| 14:50 | The path to improved outcomes: New data supporting a continued treatment approach for adults with XLH Kassim Javaid (United Kingdom) |
| 15:10 | Navigating the path: Achieving optimal patient outcomes in the real world Stuart Ralston (United Kingdom) |
| 15:25 | Q&A and interactive discussion All speakers |
| 15:40 | Summary and close Stuart Ralston (United Kingdom) |
Gedeon Richter
Is it time to challenge the positioning of anabolic therapy in the osteoporosis treatment pathway?
Meeting Room: Room 3AB
| 14.45-15.00 | First line anabolic treatment – changing the goals of osteoporosis management Richard Keen (United Kingdom) |
| 15.00-15.15 | Anabolics in the sequential treatment of bone fragility Maria Luisa Brandi (Romania) |
| 15.15-15.30 | Practical aspects of anabolic treatment in real life Peyman Hadji (Germany) |
| 15:30-15.45 | Discussion and Q&A All speakers |
Monday 17 April – 14:45 – 15:45 BST
Amgen (Europe) GmbH
Sponsored Meet-the-Expert
Denosumab: Past, Present and Future – Mechanistic Insights
Meeting Room: Room 3AB
| 14:45 – 15:45 | Denosumab: Past, Present and Future – Mechanistic Insights Kassim Javaid (UK) |